Akari Therapeutics to Host Investor and Analyst Event During the 59th American Society of Hematology Meeting
December 04 2017 - 3:01PM
Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical company
focused on the development and commercialization of innovative
therapeutics to treat orphan autoimmune and inflammatory diseases,
plans to webcast an analyst and investor event being held at the
Omni Atlanta Hotel at CNN Center in the Maple Room on December 10,
2017, beginning at 7:30 p.m. ET, with presentations beginning
promptly at 8:00 p.m. ET.
Akari Therapeutics’ management team will provide an update on
the Company’s Phase II COBALT clinical trial of Coversin™ in
patients with paroxysmal nocturnal hemoglobinuria (PNH) and an
update on the Company’s plans for Phase III trials with Coversin to
commence in the first quarter of 2018. In addition, Dr. Anita
Hill, a leading clinical investigator in PNH, will share her
perspectives on the Akari Therapeutics’ clinical development
program.
The webcast will begin at 8 p.m. ET and can be accessed under
“Events” in the Investor Relations section of the Company's website
at www.akaritx.com, as well as archived for future review.
This event is intended for institutional investors, sell-side
analysts, and pharmaceutical business development professionals.
Please RSVP in advance if you plan to attend.
About Akari TherapeuticsAkari is a
biopharmaceutical company focused on developing inhibitors of acute
and chronic inflammation, specifically the complement system, the
eicosanoid system and the bioamine system for the treatment of rare
and orphan diseases, in particular those where the complement
system or leukotrienes or both complement and leukotrienes together
play a primary role in disease progression. Akari's lead drug
candidate Coversin is a C5 complement inhibitor currently being
evaluated in paroxysmal nocturnal hemoglobinuria (PNH) and atypical
hemolytic uremic syndrome (aHUS). In addition to its C5 inhibitory
activity, Coversin independently and specifically inhibits
leukotriene B4 (LTB4) activity. Akari intends to evaluate Coversin
in two conditions, the skin and eye diseases bullous pemphigoid and
atopic keratoconjunctivitis, where the dual action of Coversin on
both C5 and LTB4 may be beneficial. Akari is also developing other
tick derived proteins, including long acting versions.
Cautionary Note Regarding Forward-Looking
StatementsCertain statements in this press release
constitute “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements reflect our current views about our
plans, intentions, expectations, strategies and prospects, which
are based on the information currently available to us and on
assumptions we have made. Although we believe that our plans,
intentions, expectations, strategies and prospects as reflected in
or suggested by those forward-looking statements are reasonable, we
can give no assurance that the plans, intentions, expectations or
strategies will be attained or achieved. Furthermore, actual
results may differ materially from those described in the
forward-looking statements and will be affected by a variety of
risks and factors that are beyond our control. Such risks and
uncertainties for our company include, but are not limited to:
needs for additional capital to fund our operations, an inability
or delay in obtaining required regulatory approvals for Coversin
and any other product candidates, which may result in unexpected
cost expenditures; risks inherent in drug development in general;
uncertainties in obtaining successful clinical results for Coversin
and any other product candidates and unexpected costs that may
result therefrom; failure to realize any value of Coversin and any
other product candidates developed and being developed in light of
inherent risks and difficulties involved in successfully bringing
product candidates to market; inability to develop new product
candidates and support existing product candidates; the approval by
the FDA and EMA and any other similar foreign regulatory
authorities of other competing or superior products brought to
market; risks resulting from unforeseen side effects; risk that the
market for Coversin may not be as large as expected; inability to
obtain, maintain and enforce patents and other intellectual
property rights or the unexpected costs associated with such
enforcement or litigation; inability to obtain and maintain
commercial manufacturing arrangements with third party
manufacturers or establish commercial scale manufacturing
capabilities; the inability to timely source adequate supply of our
active pharmaceutical ingredients from third party manufacturers on
whom the company depends; our inability to obtain additional
capital on acceptable terms, or at all; unexpected cost increases
and pricing pressures; uncertainties of cash flows and inability to
meet working capital needs; and risks and other risk factors
detailed in our public filings with the U.S. Securities and
Exchange Commission, including our Annual Report on Form 20-F filed
on March 31, 2017. Except as otherwise noted, these forward-looking
statements speak only as of the date of this press release and we
undertake no obligation to update or revise any of these statements
to reflect events or circumstances occurring after this press
release. We caution investors not to place considerable reliance on
the forward-looking statements contained in this press release.For
more information
Investor Contact:
Peter VozzoWestwicke Partners(443)
213-0505peter.vozzo@westwicke.com
Media Contact:
Mary-Jane Elliott / Sukaina VirjiConsilium Strategic
Communications+44 (0)20 3709
5700Akari@consilium-comms.com
Akari Therapeutics (NASDAQ:AKTX)
Historical Stock Chart
From Apr 2024 to May 2024
Akari Therapeutics (NASDAQ:AKTX)
Historical Stock Chart
From May 2023 to May 2024